Sarsia Seed Management
VC Fund
North Bergen, United States
Sarsia Seed Management is a VC fund in North Bergen focused on Biotechnology and Software. Sarsia Seed AS is a Norwegian Seed Capital Fund which invests in Norwegian early phase technology companies within the energy/cleantech and biotechnology/life science sectors. The fund has a total capital of 333.5 million NOK (approx, 40 mEUR/50 mUSD) and is managed by Sarsia Seed Management AS. The management company advises the Fund board regarding investment decisions. The Fundâ€:tm:s duration is expected to be 12 (+3) years. The Management Teamâ€:tm:s strength lay in its competence, experience and extensive national and international network of industrial players and co-investors. The Teamâ€:tm:s collective experience comprises an optimal balance between operations, business and specialised technology know-how, applied research, and entrepreneurship; elements which are actively used both in the vetting and follow-up of investments.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Sarsia Seed Management invests in
Stages Sarsia Seed Management invests in
Countries Sarsia Seed Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Venture - Series Unknown
- $1.5M–$3.9M
Investment Focus
Industry
- Biotechnology 4 (36%)
- Software 3 (27%)
- Pharmaceutical 2 (18%)
- Energy 1 (9%)
- Sensor 1 (9%)
Stage
- Funding Round 4 (36%)
- Venture - Series Unknown 2 (18%)
- Seed 1 (9%)
- Series A 1 (9%)
- Series B 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Erlend Skagseth
Partner
|
Partner | Total investments: 0 | Find email | |
Jon Trygve Berg
Partner
|
Partner | Total investments: 2 | Find email | |
Sveinung Hole
Senior Partner
|
Senior Partner | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Heimdall Power is a technology company specializing in smart grid solutions for the energy sector. They focus on optimizing and digitizing power grid infrastructure to enhance efficiency, reliability, and sustainability. These sensors are installed on power lines to provide real-time data on various parameters, including temperature, load, and linesag. They help in monitoring and managing the grid more effectively. Heimdall Power's mission is to revolutionize the way power grids are managed by providing real-time data and advanced analytics to improve grid performance and facilitate the transition to renewable energy sources. | $25M / Series B / Jul 16, 2024 | ||
| Heimdall Power is a technology company specializing in smart grid solutions for the energy sector. They focus on optimizing and digitizing power grid infrastructure to enhance efficiency, reliability, and sustainability. These sensors are installed on power lines to provide real-time data on various parameters, including temperature, load, and linesag. They help in monitoring and managing the grid more effectively. Heimdall Power's mission is to revolutionize the way power grids are managed by providing real-time data and advanced analytics to improve grid performance and facilitate the transition to renewable energy sources. | $3.9M / Venture - Series Unknown / Aug 20, 2020 | ||
| BrainImage is the provider of SonoClear® - an acoustic coupling fluid for enhanced ultrasound imaging. | $1.5M / Venture - Series Unknown / Jun 25, 2018 | ||
| BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers. | $12.5M / Series C / Feb 05, 2014 | ||
| APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress. | Oct 17, 2012 | ||
| BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers. | $8.8M / Series A / Jan 09, 2012 | ||
| APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress. | Nov 10, 2011 | ||
| BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers. | $1.3M / Seed / Mar 02, 2011 | ||
| Isentio is an online application that dramatically improves the bacteria identification process. It is based on research done on advanced DNA analysis methods. The end result, ripseq, is an online software tool for quick bacterial identification that focuses on analyzing clinical samples with a variety of bacteria present. | $1.5M / Jan 17, 2011 | ||
| Avexxin's therapeutic approach is built on more than a decade of research into the biological mechanisms involved in inflammatory diseases at the Norwegian University of Science and Technology. Avexxin's goal is to create a therapeutic company based on the discovery and development of novel therapeutics that address the fundamentalmechanisms involved in inflammatory diseases. | Jan 10, 2011 | ||
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sarsia Seed Management invest in?
Sarsia Seed Management invests primarily in Biotechnology, Software and Pharmaceutical startups, most often at Funding Round and Venture - Series Unknown stage. Most of the 11 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Sarsia Seed Management invest in?
Sarsia Seed Management typically joins rounds of $1.5M–$3.9M at Venture - Series Unknown. These are whole funding-round sizes, not Sarsia Seed Management's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Sarsia Seed Management took part in.
How do I contact Sarsia Seed Management?
Public channels for Sarsia Seed Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sarsia Seed Management?
The team at Sarsia Seed Management includes Erlend Skagseth (Partner), Jon Trygve Berg (Partner) and Sveinung Hole (Senior Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
